LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT. Вопр. онкол. [Internet]. 2019 Mar. 1 [cited 2026 Oct. 14];65(3):386-92. Available from: https://voprosyonkologii.ru/index.php/journal/article/view/974